NERVIANO, IT March 1st 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Anders Elm Pedersen MD, PhD, DMSc., has joined Global Clinical Development as Senior Medical Director to lead the clinical strategy and clinical development plans of the Company’s ever-growing pipeline. Anders brings extensive research, clinical development and medical affairs experience to NMS, and authored more than 80 research publications within preclinical and clinical research
“We are super excited to have Anders join our team at NMS’s crucial development phase, as we are advancing several key clinical programs with accelerated pace and building a strong team to support this progress,” said Lisa Mahnke, M.D., PhD, Board Member and Chief Medical Officer of NMS Srl and CEO and MD of NMS-US. “With his clinical development and medical affairs background and proven track record of success, Anders will bring invaluable expertise to lead this growing team.”
Dr. Pedersen commented: “I am honored to join NMS to work alongside Lisa and colleagues in Italy and the US at this transformational stage of the Company. The company is developing multiple assets with first-in-class potential and I look forward to advancing them with the team to address high unmet medical needs and improve patient lives.”
Dr. Pedersen’s most recent position was Director of Early Development and Translational Medicine at Almirall, where he had oversight off clinical trials and led clinical study design and clinical development plansAlso, he contributed translational medicine strategy across drug development stages as well as providing medical advice in relation to licensing opportunities. Previously he was Head of Medical Affairs at Merck, Denmark leading research and medical affairs activities within Neurology & Immunology (Multiple sclerosis), Fertility (Assisted reproductive technology) and Immuno-Oncology. His experience also extended to the academic world as associate professor and group leader of “Translational Immunology Group” at University of Copenhagen with a focus on drug development.
Link: 202302015-Anders Elm Pedersen appointed as Senior Medical Director_AEP
from NMSGroup
